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HaCaT as well as human primary keratinocytes con-
stitutively expressed mRNA of the human secreted
phospholipase A2 subtype groups X, V, IIA, and IID.
A similar expression pattern was also found in
human skin biopsies. Protein analysis showed that
under serum-free conditions only group X secreted
phospholipase A2 is secreted into cell culture super-
natants of HaCaT as well as human primary kerati-
nocytes, whereas the other secreted phospholipases
A2 were not detectable at protein level. HaCaT kera-
tinocytes constitutively released secreted phospholi-
pase A2 activity into the cell culture supernatant,
being re¯ected by a constant release of fatty acids.
The phorbol ester 12-O-tetradecanoylphorbol-13-
acetate, which is a potent inducer of in¯ammation in
skin, drastically reduced the mRNA level of group X
secreted phospholipase A2 and other secreted phos-
pholipase A2 subtypes as well as secreted phospholi-
pase A2 activity in cell culture supernatants. This
suggests that inhibition of secreted phospholipase A2
expression and activity as well as of fatty acid release
by 12-O-tetradecanoylphorbol-13-acetate treatment
might be a critical step impairing the integrity of the
epidermis during phorbol-ester-induced pathologic
processes in skin. The results show that group X
secreted phospholipase A2 represents the major
secreted phospholipase A2 subtype in human kerati-
nocytes and thus may indicate a physiologic role for
this enzyme in epidermis in vivo. Key words: epidermal
homeostasis/in¯ammation/phospholipase A2 inhibitors/
skin. J Invest Dermatol 116:31±39, 2001
S
ecreted phospholipases A2 (sPLA2s) comprise a subfamily
of phospholipases A2 that are structurally related but
display only modest sequence homology (Cupillard et al,
1997; Valentin et al, 1999). Many studies show that the
induction and activity of mammalian sPLA2 subtypes are
involved in proin¯ammatory processes in several tissues and organs
inducing or enhancing arachidonic acid release and prostaglandin
formation (Pfeilschifter et al, 1993; Hurt-Camejo et al, 1997; Jamal
et al, 1998; Pruzanski et al, 1998; Han et al, 1999; Murakami et al,
1999; Schiering et al, 1999; Shoda et al, 1999). Recently, the
existence of several sPLA2 subtypes within the same cell and the
location to different subcellular sites was described (Bingham et al,
1999). In several cell systems treatment with proin¯ammatory
cytokines resulted in the induction of group IIA sPLA2 at the
transcriptional level. Group IIA sPLA2 protein is present in
secretory vesicles (Vervoordeldonk et al, 1994; Bingham et al,
1999) from which it is released into the extracellular lumen. sPLA2s
are thought to be involved in in¯ammatory processes, e.g., in the
kidney (Pfeilschifter, 1994), the joints (Jamal et al, 1998), or the skin
(Andersen et al, 1994). Detailed studies concerning the regulation
of group IIA sPLA2 have been performed, e.g., in rat glomerular
mesangial cells, which release this enzyme in large amounts after
stimulation with in¯ammatory cytokines such as interleukin-1b
(IL-1b) or cAMP-elevating agents (for review see Pfeilschifter,
1994, 1995; Pfeilschifter et al, 1997).
In contrast, group V sPLA2 was identi®ed in heart, mast cells,
and macrophages and seems to be a major enzyme involved in
arachidonic acid release and prostaglandin formation (Chen and
Dennis, 1998; Sawada et al, 1999; Shinohara et al, 1999). The group
IIA and the group V sPLA2s are thought to be functionally
redundant (Murakami et al, 1998). It has been reported that these
enzymes show differences in their substrate speci®city concerning
the phospholipid head groups, however, suggesting that group V
sPLA2 works better on biologic membranes than group IIA sPLA2
(Han et al, 1999; Janssen et al, 1999). Moreover, Bingham et al
(1999) unraveled the subcellular location of these sPLA2 subtypes in
bone-marrow-derived mast cells, showing that group V is located
in perinuclear membranes similarly to enzymes involved in
eicosanoid biosynthesis, whereas group IIA sPLA2 is present in
secretory granules for exocytosis. This study implies that these
enzymes exert different functions and thus they are not redundant.
The group IIC sPLA2 was found in testis of rat and mouse and
seems to be a nonfunctional pseudogene in humans (Tisch®eld,
1997). This subtype is thought to be involved in sperm transport
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and fertilization in rodent testis (Chen et al, 1997). Several novel
subtypes identi®ed are the group IID, IIE, IIF, and X sPLA2s,
which are found in different murine tissues (Valentin et al, 1999). A
group IID and recently also a group IIE were identi®ed in human
tissues (Ishizaki et al, 1999; Suzuki et al, 2000), but a human
ortholog has not been found so far for group IIF sPLA2. The
functions of most of these novel sPLA2 subtypes remain to be
elucidated.
A human group X sPLA2 was found to be expressed in tissues
related with in¯ammatory responses (Cupillard et al, 1997) aswell as in
alveolar epithelial cells of human lung (Hanasaki et al, 1999). This
sPLA2 subtype has speci®c structural features and its chromosomal
location is distinct from those of other sPLA2s (Cupillard et al, 1997).
GroupX sPLA2 was found to release arachidonic acid more ef®ciently
than other human sPLA2 groups when added exogenously to
mammalian cells, implicating a potential role in eicosanoid
biosynthesis (Hanasaki et al, 1999; Bezzine et al, 2000).
In the skin, however, a function of sPLA2 distinct from
in¯ammation was described. The catalytic action of sPLA2 was
found to be crucial for epidermal homeostasis, which is important
for keeping the membrane permeability barrier intact against excess
water loss (Mao-Qiang et al, 1995, 1996). This permeability barrier
is located within the extracellular, lipid-enriched domain of the
stratum corneum (Lampe et al, 1983). In this domain sPLA2 and
many other lipid-hydrolyzing enzymes such as sphingomyelinase,
triacylglycerol hydrolase, as well as certain proteases were identi®ed
in lamellar granules (also called lamellar bodies; Tinois et al, 1989).
These are secretory organelles responsible for delivering lipids into
the intercellular space building up the permeability barrier. The
function of sPLA2 is to hydrolyze free fatty acids from polar lipids to
form more nonpolar lipids, which predominate in the stratum
corneum. This action of sPLA2 might be an important process for
the maintenance of epidermal integrity but also during wound
healing and skin repair. Only little information is yet available,
however, as to which sPLA2 subtypes exist in the human skin and
how individual subtypes contribute to the structural and functional
integrity of skin. Recent studies describe the localization of the
pancreatic group IB sPLA2 between the stratum corneum and
stratum granulosum of human skin, but group IIA sPLA2 was not
found (Maury et al, 2000; Mazereeuw-Hautier et al, 2000). Other
sPLA2 subtypes were not considered in this study, however.
Using the human keratinocyte cell line HaCaT, human primary
keratinocytes, and human skin biopsies we identi®ed mRNAs of
the sPLA2 subtypes IIA, IID, V, and X with group X sPLA2 being
the predominant species. On the protein level we detected only
group X sPLA2 in cell lysates and cell culture supernatants of
HaCaT cells and human primary keratinocytes cultured under
serum-free conditions, indicating that this is the major enzyme
secreted by these cells under these conditions. Moreover, we show
that the potent in¯ammatory phorbol ester 12-O-tetradecanoyl-
phorbol-13-acetate (TPA) inhibited the mRNA expression of
group X sPLA2 and also of the other sPLA2 subtypes.
MATERIALS AND METHODS
Cell culture HaCaT cells (Boukamp et al, 1988) were cultured routinely
in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), penicillin (100 units per ml), and streptomycin
(100 mg per ml). For experiments, cells were transferred to plastic Petri
dishes (Falcon, 3.5 cm with 1 ml medium or 10 cm diameter with 5 ml
medium) and cultured for 72 h in DMEM containing 2.5% FBS to
subcon¯uency. Twenty-four hours prior to the experiment the serum
concentration was further reduced to 0.25% FBS. During the time course
of the experiments cells were kept in DMEM without serum. For analysis
of fatty acid release HaCaT cells were kept in DMEM plus 0.1% fatty-acid-
free bovine serum albumin (BSA).
Human primary keratinocytes were cultured in serum-free keratinocyte
medium KBM2 (Clonetics) using standard protocols as described earlier
(Stein et al, 1997).
Analysis of sPLA2 mRNA expression by reverse transcriptase
polymerase chain reaction (RT-PCR) HaCaT as well as human
primary keratinocyte cell cultures were washed twice with phosphate-
buffered saline (PBS) and harvested using a rubber policeman. Total cellular
RNA was extracted from the cell pellets using the guanidinium
isothiocyanate-phenol-chloroform method (Sambrook et al, 1989).
Human skin samples, which were frozen in liquid nitrogen immediately
after surgery, were homogenized in guanidinium isothiocyanate with an
ultra-turrax-homogenizer and RNA was extracted as described above. For
excluding contamination with DNA, treatment of RNA preparations with
RNase-free DNase I (Roche Diagnostics, Mannheim, Germany) was
performed before RT-PCR.
Expression of mRNA for the different sPLA2 subtypes was investigated
by RT-PCR using a total of 5 mg of RNA. First strand cDNA was
transcribed with superscript II RNase H-RT obtained from Gibco BRL
and OligodT 15-Primer (Promega). From the reverse transcriptase product
(cDNA) aliquots of 500 ng were taken for PCR with the primers to be
tested. From poly-A+ mRNA of lung 0.1 mg were used for the reverse
transcription and an aliquot corresponding to 20 ng of cDNA was taken for
PCR. PCR was performed on a Perkin Elmer Thermal Cycler with
speci®c primers for each subtype and REDTaq DNA polymerase (Sigma,
Munich, Germany): group IB, sense, 5¢-aactccttgtgctagctgtgct-3¢; antisense,
5¢-cttcttggtgtccaggttct, ampli®ed product 428 bp; group IIA, sense, 5¢-
gactgttgctacaaacgtctggag-3¢; antisense, 5¢-aggagagcagtagaaggctggaaa-3¢, am-
pli®ed product 437 bp; group IID, sense, 5¢-ggtcaagcaagtgactggaaaatg-3¢;
antisense, 5¢-agaaacgcagtcgcttctggtaggt-3¢, ampli®ed product 311 bp; group
V, sense, 5¢-acattcgcacacagtcctac-3¢; antisense, 5¢-tgagttggaggagagctctt-3¢,
ampli®ed product 452 bp; group X, sense, 5¢-ccaggatattacgtgtgcac-3¢;
antisense, 5¢-gtttgggctaagcagttagc-3¢, ampli®ed product 327 bp; glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), sense, 5¢-accacagtccatgccat-
cac-3¢; antisense, 5¢-tccaccaccctgttgctgta-3¢, ampli®ed product 452 bp.
Semi-quantitative RT-PCR For semiquantitative RT-PCR the
number of ampli®cation steps was tested ®rst for linearity with different
dilutions of reverse transcriptase product. Then GAPDH was performed for
an equivalent quantity of the reverse transcriptase reaction. The different
cDNA probes were ampli®ed in a prepared mastermix containing dNTPs,
speci®c primers, and Red Taq-polymerase (Sigma) in the corresponding
PCR buffer.
For the PCR reactions the cycling parameters were optimized as follows:
group IIA, 94°C for 1 min (one cycle) followed immediately by 94°C for
1 min, 60°C for 1 min 30 s, and 72°C for 3 min (32 cycles); group IID,
94°C for 1 min followed immediately by 94°C for 30 s, 60°C for 30 s, and
72°C for 30 s (36 cycles); group V, 94°C for 1 min (one cycle) followed
immediately by 94°C for 30 s, 54°C for 45 s, and 72°C for 2 min (33
cycles); group X, 94°C for 1 min (one cycle) followed immediately by
94°C for 30 s, 50°C for 30 s, and 72°C for 30 s (34 cycles); GAPDH, 94°C
for 1 min (one cycle) followed immediately by 94°C for 1 min, 60°C for
1 min, and 72°C for 2 min (23 cycles).
Final extension phase for the PCRs of all subtypes was 10 min at 72°C.
PCR products were separated on 2% agarose gels containing 0.5 mg per ml
ethidium bromide and were visualized with an ultraviolet-gel camera
(Biorad, Munich, Germany).
Northern blot analysis Samples of 30 mg of RNA were separated on
1.4% agarose/formaldehyde gels and transferred to a Gene Screen
membrane. After ultraviolet crosslinking and prehybridization in
Ultrahyb buffer (Ambion, Austin, TX) for 1 h the ®lters were hybridized
in Ultrahyb buffer for 16 h at 68°C to [a-32P]dCTP-labeled cDNA inserts
from groups IIA, V, and X sPLA2. DNA probes were radioactively labeled
with [a-32P]dCTP by random priming. Finally, the ®lters were washed
twice with 2 3 sodium citrate/chloride buffer (SSC)/0.1% sodium dodecyl
sulfate (SDS) for 2 3 10 min and several times at 68°C with 0.1 3 SSC/
0.1% SDS. The signal was detected and quanti®ed with a phosphorimager
BAS 1500 from Fuji (Raytest, Straubenhardt, Germany). To correct for
variations in RNA loading the respective cDNA probes were stripped and
the blots were hybridized for 16 h with Ultrahyb buffer at 42°C to the [a-
32P]dCTP-labeled cDNA insert for GAPDH. The numbers at the top of
the northern blot represent the corrected density expressed as the
percentage of group X sPLA2 mRNA found in cells at time point zero.
sPLA2 activity assay sPLA2 activity in the supernatant of HaCaT cells
was determined with [1-14C]-oleate-labeled membranes from Escherichia coli
as a substrate as described previously (Scholz et al, 1999). Assay mixtures
(750 ml) contained 100 mM Tris/HCl (pH 7.0), 1 mM CaCl2, [1-14C]-
oleate-labeled E. coli membranes (approximately 5000 cpm), and the
enzyme-containing supernatants of the cell cultures. During incubation less
than 5% of substrate was hydrolyzed. The reaction mixture was incubated
for 1 h at 37°C in a thermomixer. The reaction was stopped by the addition
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of 50 ml 1 mM ethyleneglycol-bis(b-aminoethyl ether)-N,N,N¢,N¢-
tetraacetic acid (EGTA)/1 N HCl and 800 ml ethyl acetate. After
extraction of the lipids the organic phase was dried in a vacuum
concentrator. Then the lipids were dissolved in 50 ml ethyl acetate and
separated by thin layer chromatography on silica gel G 60 plates using the
organic phase of ethyl acetate:isooctane:acetic acid:water (110:50:20:100 by
volume) as a solvent system. Detection and quanti®cation of the released
fatty acid were performed with a linear analyzer (Berthold, Wildbad,
Germany). In parallel experiments extraction ef®ciency was determined to
be greater than 95%.
Measurement of fatty acid release For measuring fatty acid release
HaCaT cells were cultured in 3.5 cm dishes to subcon¯uency (about 106
cells per dish) in 2 ml cell culture medium. After medium change cells were
prelabeled for 24 h with [1-14C]-linoleic acid or [1-14C]-oleic acid (0.3 mCi
per ml) in 1 ml DMEM plus 1 mg per ml fatty-acid-free BSA. After washing
the cell cultures twice with PBS/BSA (1 mg per ml) and adding 1 ml of
fresh medium the supernatants were collected at different time points as
indicated. Supernatants were measured in a b-counter to detect the
amounts of released [1-14C]-labeled fatty acids. The incorporation rate of
the different fatty acids into keratinocytes was evaluated by extracting the
cells with chloroform:methanol:1 N HCl (4:2:2 by volume) and measuring
the radioactivity of the organic phase in a b-counter. For all three fatty acids
the incorporation rate after 24 h was about 90%. The amounts of labeled
fatty acids in the supernatants represent about 0.2% of total labeled lipids.
The amount of lipid peroxidation products derived nonenzymatically or
enzymatically from linoleic acid under the conditions of prelabeling did not
exceed 5% (unpublished observation).
Western blot analysis sPLA2 protein secretion by HaCaT cells was
assayed by precipitating 5 ml of the culture supernatants with 2 ml of 20%
trichloroacetic acid. SDS polyacrylamide gel electrophoresis (PAGE) using
a 15% polyacrylamide gel was performed under nonreducing conditions
according to Laemmli (1970). Cell lysates were obtained after removal of
the medium by incubating the cell layer on ice for 10 min in 500 ml per
10 cm dish of 50 mM Tris/HCl pH 7.5, 150 mM NaCl, 1 mM
phenylmethylsulfonyl ¯uoride, 10 mg per ml leupeptin, 0.5% Triton X-
100. One milligram of cellular protein was diluted in 150 ml Laemmli
sample buffer and was separated on a 14 cm 3 14 cm polyacrylamide gel
with 8 mm slots. As controls 500 ng of human recombinant groups IIA and
X sPLA2 protein were also loaded on the gel. For western blotting proteins
were transferred to PVDF membranes for 30 min at 0.8 mA per cm2. Non-
speci®c binding was blocked with 2% (wt/vol) BSA in PBS-Tween 20 for
1 h at room temperature followed by incubation with a 1:100 dilution of a
primary antibody against the human group X sPLA2. The antiserum was
generated in rabbits against the peptide PKTERYSWQC (amino acid
sequence 101±111; Cupillard et al, 1997), conjugated to keyhole limpet
hemocyanin. Then the blot was incubated with horseradish-peroxidase-
conjugated goat antirabbit IgG. After washing, peroxidase activity was
detected by developing the blots by the enhanced chemiluminescence
method (Amersham, Freiburg, Germany). The minimum amount of group
X sPLA2 protein recognized by the serum at 1:100 dilution is 300±400 ng.
Calculation of the amounts of group X sPLA2 protein on the western blots
was performed by densitometric analysis using human recombinant group
X protein as standard in a range of 500 ng to 1 mg.
Cross-reactivity of this antiserum with other human and murine sPLA2
subtypes was tested by loading 500 ng of the respective recombinant,
refolded proteins (human groups IB, IIA, IID, V, X) on a gel and
performing PAGE and western blot analysis with a 1:100 dilution of the
human group X antiserum under nonreducing conditions. The source of all
these enzymes will be given elsewhere. The structures of the proteins were
con®rmed by electrospray mass spectrometry to show that all disul®des
were intact.
Enzyme-linked immunosorbent assay (ELISA) for analysis of
sPLA2 protein In order to detect group IIA sPLA2 in the cell culture
supernatants of HaCaT cells an ELISA from Boehringer Mannheim
(Mannheim, Germany) designed against the human group IIA sPLA2 was
performed according to the manufacturer's instructions. This ELISA detects
puri®ed human group IIA sPLA2 in a range of 1-500 ng per ml. To analyze
a cross-reaction of the sPLA2 antibody used in this ELISA with other sPLA2
subtypes, up to 500 ng of puri®ed human recombinant protein of the group
V sPLA2, kindly provided by Dr. Wonhwa Cho (Department of
Chemistry, University of Illinois, Chicago, IL), and also 500 ng of the
group X were used as positive controls. We found that the antibody against
the human group IIA used as standard in this ELISA cross-reacted with
human group V sPLA2. In the standard curve both enzymes were detected
with an equal sensitivity, whereas group X sPLA2 was not detected (data
not shown).
Statistical analysis Data are presented as mean 6 SEM resulting from
three independent experiments performed in triplicate (n = 3), or mean
6 SD when showing one representative experiment out of three performed
in triplicate.
Statistical analysis was performed by Student's t test to determine
signi®cant differences among two groups. *, #, +p < 0.05. For comparing
all LY-311727 concentrations with the control group statistical analysis was
performed by repeated measures ANOVA followed by Dunnett's test. A
probability less than 0.05 was de®ned as signi®cant.
Materials [1-14C]-oleic acid and [1-14C]-linoleic acid (speci®c acitivity
50 mCi per mmol) were from Biotrend, KoÈln, Germany, and [a-32P]dCTP
(110 TBq per mmol) was from Amersham. Methyl arachidonyl
¯uorophosphonate was obtained from Calbiochem, Bad Soden/Ts,
Germany. LY-311727 was kindly provided by Lilly Research
Laboratories (Indianapolis, IN).
The primers for human GAPDH for semiquantitative RT-PCR were
kindly provided by Dr. Heiko MuÈhl, Center of Pharmacology, University
Hospital Frankfurt, Germany. The ELISA for detection of human group
IIA sPLA2 was a generous gift of Professor Dr. Ulrich Tibes, Roche
Diagnostics, Department of Molecular Pharmacology, Mannheim,
Germany. Poly A+ RNA from human lung was obtained from Clontech
(Heidelberg, Germany).
Immobilon-PVDF membranes were from Millipore (Eschborn,
Germany) and Nylon membranes (Gene Screen) were purchased from
NEN Life Science (KoÈln, Germany). All cell culture media and nutrients
were from Gibco BRL (Eggenstein, Germany), and all other chemicals
used were from Merck (Darmstadt, Germany), Sigma (Munich, Germany),
or Fluka (Deisenhofen, Germany).
RESULTS
mRNA expression of sPLA2 subtypes in HaCaT
keratinocytes, in human keratinocytes, and in human
skin mRNA was extracted from subcon¯uent HaCaT cell
cultures grown under serum-free conditions, and RT-PCRs
were performed under the conditions described in Methods with a
set of primers speci®c for the human groups IB, IIA, IID, V, and X
sPLA2s. The identity of the PCR products was con®rmed by
sequence analysis.
The qualitative analysis shown in Fig 1(a) indicates that under
serum-free conditions HaCaT cells constitutively express groups IIA,
IID, V, and X sPLA2 mRNA. Southern blot analysis indicated that
group X sPLA2 is the predominant sPLA2 subtype expressed in
HaCaT cells (data not shown). According to this analysis, sPLA2
subtypes can be ranked in the following order: group X > group V >
group IIA > group IID. As the group IID sPLA2 mRNA is present
only at very low levels (indicated by the arrows in the lanes of group
IID sPLA2) we did not further study the expression of this subtype.
In order to compare the mRNA expression pattern of sPLA2
subtypes in HaCaT cells with that in human primary keratinocytes
and in human skin, total RNA from cell cultures of human primary
keratinocytes and from human biopsies was extracted and RT-
PCR was performed with primer sets speci®c for the sPLA2 groups
IB, IIA, IID, V, and X. The data in Fig 1(a) show the same
expression pattern as for HaCaT cells: groups IIA, IID, V, and X
sPLA2 mRNA are constitutively expressed both in human primary
keratinocytes and in the human skin biopsies.
With the primers and under the experimental conditions used
group IB sPLA2 mRNA was not detected in HaCaT cells and in
human primary keratinocytes and human skin in vivo (Fig 1b). As
positive control for group IB sPLA2 RT-PCR with the primers
was performed with poly A+ RNA from human lung, which is
known to express this sPLA2 subtype (Matsuda et al, 1987).
Detection of sPLA2 protein in HaCaT cells and in human
primary keratinocytes by western blot analysis To study the
subtypes of sPLA2 secreted from HaCaT cells and human primary
keratinocytes, we performed western blot analysis of protein
precipitated from cell culture supernatants and cell lysates from cells
cultured under serum-free conditions.
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Using an antiserum raised against a group X sPLA2-speci®c
peptide, strong immunoreactivity towards puri®ed recombinant
human group X sPLA2, but no cross-reactivity with puri®ed
recombinant human groups IB, IIA, IID, or V sPLA2 proteins, was
observed (Fig 2a).
With this antiserum group X sPLA2 protein was detectable in the
cell culture supernatants of HaCaT cells as well as human primary
keratinocytes (Fig 2b). The concentration of group X protein
released into the supernatant was determined by densitometric
analysis to 200 ng per ml.
In order to analyze whether there is also group IIA or group V
sPLA2 present in cell culture supernatants of HaCaT cells and
human primary keratinocytes, we used an ELISA from Boehringer
Mannheim, which detects both sPLA2 subtypes in a range between
1 and 500 ng per ml (see Methods). As positive controls for standard
curves we used up to 500 ng of both human recombinant group IIA
and group V sPLA2. With this method we did not detect a positive
signal in the cell culture supernatants of HaCaT cells or human
primary keratinocytes, indicating that group IIA and group V
sPLA2 are not secreted by these cells (data not shown).
Group X sPLA2 was also detectable in cell lysates of HaCaT cells
as well as human primary keratinocytes (Fig 2c). From these results
we conclude that the group X sPLA2 is the major enzyme secreted
by keratinocytes under serum-free conditions.
Detection of sPLA2 activity in the supernatants of HaCaT
cell cultures As sPLA2 subtype expression in primary human
keratincytes was similar to that in HaCaT cells, we used this
keratinocyte line for the analysis of sPLA2 activity. Therefore,
supernatants from HaCaT cell cultures were collected at different
time points after medium change, and the enzymatic activity was
determined using [14C]-oleic acid-labeled E. coli membranes as
substrate. sPLA2 activity increased immediately after medium
change, reaching a plateau after 4±8 h (Fig 3), and may essentially
be attributed to group X sPLA2, the only subtype detected in the
culture supernatant (Fig 2b). sPLA2 activity is expressed as factor of
increase in free [1-14C]-oleic acid.
Release of free fatty acids from HaCaT cells In order to
measure the release of free fatty acids HaCaT cells were prelabeled
for 24 h with [1-14C]-linoleic or [1-14C]-oleic acid. Fresh culture
medium was added and removed after different incubation times,
and the amounts of free fatty acids were measured in a b-counter.
The values measured in the supernatants at zero time did not
exceed background values (about 40 cpm per ml).
The data in Fig 4 show an increasing release of the different fatty
acids from HaCaT cells with time. The time course correlates with
the increase in sPLA2 activity in the supernatants (see Fig 3).
Inhibition of sPLA2 activity and fatty acid release by LY-
311727 and Pyr-1 In order to con®rm that an sPLA2 participates
in the release of fatty acids, we ®rst incubated HaCaT cells in the
presence of LY-311727, known as a potent inhibitor of groups IIA
and V sPLA2 (Balsinde et al, 1999) and group X sPLA2 (Bezzine et al
Figure 1. Identi®cation of sPLA2 subtypes in HaCaT cells, in
human primary keratinocytes, and in human skin by RT-PCR.
Total RNA was extracted from HaCaT cells, human primary keratino-
cytes, and human skin samples, and after DNase I treatment of the RNA
probes RT-PCR was performed with speci®c primers for the human
groups IIA, IID, V, and X sPLA2 under the conditions described in
Methods. The bands for group IID sPLA2 are indicated by arrows. The
upper band in the lane of group IID sPLA2 derived from unspeci®c binding
as was checked by sequence analysis. This experiment was repeated four
times with similar results. RT-PCR for group IB sPLA2 was performed in
the cell cultures as well as in human skin samples, and as a positive control
for human group IB sPLA2 poly A+ RNA from human lung was used.
Abbreviations: HPK, human primary keratinocytes; n.t., no template.
Figure 2. Western blot analysis of group X sPLA2. HaCaT cells were
incubated in serum-free DMEM for the periods indicated. Cell culture
supernatants and cellular proteins were collected after the time points
indicated. Human primary keratinocytes were cultured as described.
Supernatants and cell lysates were harvested without further subcultivation
of these cells. Five hundred nanograms of human recombinant groups IB,
IIA, IID, V, and X sPLA2s were blotted and the western blot was incubated
with an antiserum created against a peptide sequence speci®c for group X
sPLA2 (see Methods). Proteins from 5 ml of cell culture supernatants of
HaCaT cells and human primary keratinocytes were precipitated and
separated by SDS-PAGE under nonreducing conditions as described in
Methods. Western blot analysis was performed using the antiserum against
group X sPLA2 at 1:150 dilution. As positive controls recombinant human
groups IIA and X sPLA2 were also blotted. One milligram protein of cell
lysates from HaCaT cells or human primary keratinocytes was separated by
SDS-PAGE under nonreducing conditions, and detection of group X
sPLA2 was performed as described above. Representative western blots out
of three are shown for supernatants as well as for cell lysates.
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2000), but not of the pancreatic-type group IB sPLA2 or cytosolic
PLA2 (Schevitz et al, 1995). sPLA2 activity in the cell culture
supernatants was determined after an 8 h incubation of the cells in
the presence of the inhibitor. Figure 5 (a) shows that sPLA2
activity was signi®cantly reduced by about 50%±70% with LY-
311727 at a concentration of 50 mM. Fatty acid release (Fig 5b)
from HaCaT cells prelabeled with [1-14C]-oleic or [1-14C]-linoleic
acid was inhibited by about 30%±50% in the presence of LY-
311727 (50 mM). These data indicate that at least a part of the
released fatty acids can be attributed to group X sPLA2, as group
IIA and group V sPLA2 were not detected in these cells.
Accordingly, Pyr-1 [3-(2,6-dichlorophenylsulfonylamino)-4-(2-
(4-acetamido) pyridyl)-5-(3-(4-¯uorophenoxy) benzyl(thio)-(1H)-
pyrazole], a compound that was found to inhibit human group IIA
sPLA2 in vitro with a 120-fold selectivity compared with human
group X sPLA2 (Bezzine et al, 2000), had no effect on the enzyme
activity or on the fatty acid release measured 8 h after medium
change, when given in concentrations up to 30 mM (data not
shown).
Effect of phorbol ester TPA on sPLA2 activity and fatty acid
release in HaCaT cell culture supernatants Phorbol esters
such as TPA are known to induce arachidonic acid release and
prostaglandin synthesis in mouse keratinocytes in vitro and
epidermis in vivo. This is predominantly due to the activation of
cytosolic PLA2 (Kast et al, 1993; Lo et al, 1998). Nothing is known
about the effects of phorbol esters on fatty acid metabolism and
regulation of sPLA2s in human keratinocytes, however. We
therefore asked whether TPA can modulate sPLA2 expression
and activity as well as release of fatty acids. After prelabeling with
[1-14C]-oleic or [1-14C]-linoleic acid for 24 h and subsequent
medium change, HaCaT cells were treated for 8 h with TPA
(1 mM) or dimethylsulfoxide as control (0.05%), and the release of
labeled fatty acids into the cell culture supernatant was analyzed. In
similar experiments cell culture supernatants were collected for
analysis of sPLA2 activity.
The data in Fig 6(a) show that TPA inhibited sPLA2 activity in
the supernatant by about 50%. TPA treatment also reduced the
levels of oleic as well as linoleic acid in the cell culture supernatants
from prelabeled cells by about 40% (Fig 6b).
In¯uence of TPA on mRNA expression of groups IIA, V,
and X sPLA2 We next asked whether the mRNA expression of
individual sPLA2 subtypes is affected by TPA. Recently we
reported that TPA downregulates group IIA sPLA2 mRNA
induction in rat glomerular mesangial cells through a protein-
kinase-C-mediated mechanism (Scholz et al, 1999).
Performing semiquantitative RT-PCR we observed that upon
medium change the mRNA level of group X sPLA2 increased after
4 h, reaching a plateau after 8 h in untreated cells (Fig 7). This time
course corresponds to the sPLA2 activity shown in Fig 3. In
addition, mRNA levels of group V and group IIA sPLA2 also
slightly increased with time up to 24 h.
In contrast, TPA led to a marked decrease of the mRNA levels
of group X sPLA2 starting at 4±8 h and being maximally reduced at
24 h after treatment. This inhibition of mRNA expression
correlated with the reduced sPLA2 activity and fatty acid release
shown in Fig 6. The mRNA levels of group IIA and group V
sPLA2 were also clearly reduced 24 h after TPA treatment
compared with controls. These data suggest that the three different
sPLA2 subtypes are downregulated upon TPA application, the most
prominent effect being observed for group X sPLA2.
A similar kinetic of group X sPLA2 mRNA expression and
downregulation by TPA was also detectable by northern blot
analysis (Fig 8). Quantitative analysis of group X sPLA2 mRNA
expression showed that mRNA levels were reduced by about 40%
at 4±16 h after TPA treatment concomitantly with the decrease in
sPLA2 activity and fatty acid release (Fig 6).
The other sPLA2 subtypes were not detectable by this method,
probably due to the low mRNA expression levels.
DISCUSSION
Several studies report on a role of sPLA2 as a proin¯ammatory
enzyme in skin of humans and animals. Overexpression of human
group IIA sPLA2 in the skin of transgenic mice resulted in
hyperkeratosis, epidermal hyperplasia, and adnexal hyperplasia,
which re¯ect the symptoms observed in skin disorders including
human psoriasis (Grass et al, 1996). Other groups have examined
the effects of intradermal injection of sPLA2 from snake venom and
of the pancreatic-type group IB sPLA2 in rabbit and swine
(Pruzanski et al, 1986; Nair et al, 1993) causing the induction of a
Figure 3. Detection of sPLA2 activity in HaCaT cell culture
supernatants. HaCaT cells were cultured for 72 h in 10% FBS and then
incubated for a further 16 h in 0.25% FBS. After medium change to serum-
free DMEM cell culture supernatants were collected at once or at different
time points. sPLA2 activity was determined in the cell culture supernatants
using [14C]-oleic-acid-labeled E. coli membranes as described in Methods.
Each value represents the mean of three independent experiments 6 SEM
(n = 3).
Figure 4. Release of different fatty acids into the cell culture
supernatants of HaCaT cells. HaCaT cells were prelabeled for 24 h
with [1-14C]-oleic acid (j) or [1-14C]-linoleic acid (d; each 0.3 mCi per
106 cells). After thorough washing with PBS/BSA and incubation in
DMEM plus 1 mg per ml fatty-acid-free BSA cells were incubated for the
indicated periods. Then the cell culture supernatants were collected and
measured in a b-counter. The release of fatty acids is expressed as cpm
per ml. Each value represents the mean of three parallel onsets 6 SD. The
data are representative for three different experiments with similar results.
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transient erythema as well as in¯ammatory cell in®ltration and
epidermal hyperplasia. These studies show that high levels of sPLA2
in the skin induce marked changes of skin phenotype such as
epidermal hyperplasia. The acute in¯ammatory reaction upon
intradermal injection may critically depend on high local sPLA2
concentrations as Grass et al (1996) did not observe such effects in
transgenic mice overexpressing group IIA sPLA2 in the skin.
The strong effects of sPLA2s upon local application or ectopic
expression led us to analyze the subtype spectrum of this enzyme
family expressed in keratinocytes in culture and in vivo. Semi-
quantitative PCR and southern blot analysis indicate that HaCaT
cells, human primary keratinocytes, and human skin express the
four different sPLA2 subtypes IIA, IID, V, and X. The novel
human group IIE sPLA2 (Suzuki et al, 2000) was not detectable
(data not shown).
In addition, the mRNA steady-state levels in HaCaT cells
coding for the different sPLA2s were strikingly different in the
following order: group X > group V > group IIA > group IID. The
mRNA levels of all sPLA2 subtypes increased during the time
course of the experiment probably due to a stimulatory effect of the
medium change. Group IB sPLA2 mRNA was not detectable in
our hands in HaCaT cells, in human primary keratinocytes, or in
human skin, using primers generating a positive signal with lung
mRNA. Recently, group IB sPLA2 was found by immunohis-
tochemistry studies to be localized to the stratum corneum of
human skin (Mazereeuw-Hautier et al, 2000) and was also cloned
from human epidermis (Maury et al, 2000). The authors did not
examine the cross-reactivity of the antibody used with other sPLA2
subtypes, however. The discrepancy between our results and the
observations by Maury and coworkers (2000) might be explained
by a weaker expression of group IB sPLA2 in skin than in lung.
Moreover, there might be a strong dilution of group IB sPLA2
mRNA in RNA extracts from total skin biopsies, which also
include some RNA from the dermis where this enzyme is not
expressed (Maury et al, 2000).
The antibody generated against the group X sPLA2 did not
cross-react with any other sPLA2 subtypes investigated in this study
and was able to detect about 200 ng per ml of group X sPLA2 in
supernatants of HaCaT as well as human primary keratinocytes. We
also detected group X sPLA2 protein in cell lysates indicating that
the early increase of extracellular sPLA2 activity was most probably
due to secretion of the enzyme from intracellular stores. The action
of an exogenous sPLA2 on the outer membrane of cells is an
important prerequisite for a functional role in hydrolysing
phospholipids for maintaining the epidermal permeability barrier.
This enzyme might contribute to the hydrolysis of polar lipids from
suprabasal layers of the skin providing free fatty acids that are
necessary for the synthesis of complex lipids forming the
permeability barrier (Redoules et al, 1998; Ziboh et al, 2000).
This view has to be supported by immunohistochemistry
determining the localization of group X sPLA2 in human epidermis
in detail. Group IIA as well as group V sPLA2 protein would not be
detected in keratinocytes in vivo and in vitro despite a modest
increase of the corresponding mRNA species.
Incubation of keratinocytes with heparin or 1 M NaCl did not
result in an enhanced extracellular sPLA2 activity (data not shown)
indicating the absence of membrane-associated sPLA2, including
group IIA and group V sPLA2, which are known to bind tightly to
cell surface proteoglycans (Cupillard et al, 1997). Interestingly,
Murakami et al (1999) showed that group X sPLA2 does not bind to
a heparin-Sepharose column, suggesting that this subtype does not
associate with cell surface proteoglycans.
In summary, according to RT-PCR and northern blot and
western blot analysis sPLA2 activity in human keratinocytes is
derived from group X sPLA2. This sPLA2 subtype ef®ciently
hydrolyzes phosphatidylcholine (Murakami et al, 1999), a major
phospholipid of the outer lea¯et of the plasma membrane. A recent
report by Bezzine et al (2000) describes an ef®cient release of
arachidonic acid from adherent cell cultures by exogenously added
group X sPLA2 indicating that this enzyme is involved in
prostaglandin biosynthesis. This does not exclude, however, that
group X sPLA2 also hydrolyzes other phospholipid species different
from phosphatidylcholine (Cupillard et al, 1997).
The absence of group IIA or group V sPLA2 protein despite their
mRNA expression suggests that these enzymes are probably not
involved in homeostatic processes in the epidermis. This is
supported by the fact that group IIA sPLA2 protein is not
detectable in skin under physiologic conditions (Mazereeuw-
Hautier et al, 2000), and the high levels of this enzyme obtained in
human psoriatic skin (Andersen et al, 1994) will probably never be
reached in intact nonin¯amed epidermis. In keratinocyte cultures
group IIA and/or group V sPLA2 might appear after stimulation,
e.g., by proin¯ammatory cytokines or growth factors. In this
respect indirect evidence was given by Thommesen et al (1998)
who showed that in tumor-necrosis-factor-a-stimulated HaCaT
cells the release of arachidonic acid was reduced by the sPLA2
inhibitor LY-311727, indicating a participation of an exogenous
sPLA2 in this process. The responsible subtype was not identi®ed in
Figure 5. Inhibition of sPLA2 activity and fatty acid release in
HaCaT cells by LY-311727. (a) sPLA2 activity; (b) fatty acid release.
HaCaT cells were treated for 8 h with the indicated concentrations of LY-
311727 and then sPLA2 activity was determined as described in Methods.
Each value represents the mean of three independent experiments 6 SEM
(n = 3). *p < 0.05, ANOVA followed by Dunnett's test. Cells were
prelabeled for 24 h with [1-14C]-oleic acid or [1-14C]-linoleic acid (each
0.3 mCi per ml). After medium change they were incubated for 8 h in the
absence or presence of LY-311727 (50 mM). Then the release of fatty acids
was analyzed as described above. Each value represents the mean of three
independent experiments 6 SEM (n = 3). #p < 0.05 (oleic acid), +p < 0.05
(linoleic acid), Student's t test.
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this study, however. In a recent study induction of group IIA or
group V sPLA2 protein in activated human primary keratinocytes
was recently shown by Rys-Sikora et al (2000). In their study,
however, other sPLA2 subtypes such as group X sPLA2 were not
investigated. Moreover, one has to consider that it is important
whether cells were cultured in serum-containing or in serum-free
medium. In our study we tried to prevent additional stimulation by
serum factors, which might be the reason why we did not detect
group IIA or V sPLA2 protein.
In this study we also followed the release of oleic and linoleic
acid, which are known to be preferentially localized to the sn-2
position of phospholipids. The release of free fatty acids from cells
represents a steady-state equilibrium between hydrolysis and the
reesteri®cation of the free fatty acids. Thus, the increased release of
oleic acid over linoleic acid (Fig 4) may be due to a less effective
reincorporation of this fatty acid into phospholipids.
Using the sPLA2 inhibitor LY-311727, we found a partial
inhibition of sPLA2 activity and fatty acid release from HaCaT cells.
This substance is known to inhibit a variety of sPLA2s (Chen and
Dennis, 1998; Bezzine et al, 2000), whereas it does not inhibit
intracellular PLA2s or group IB sPLA2 (Schevitz et al, 1995). In
cultures of rat mesangial cells that release group IIA sPLA2
(Pfeilschifter et al, 1993), 10 mM of this compound completely
inhibited the enzyme activity (unpublished results). In HaCaT cells,
however, a concentration of 50 mM was required to inhibit sPLA2
activity in the supernatant by 70%. Murakami et al (1999) reported
that group X sPLA2 activity was indeed resistant to 10 mM of LY-
311727, and Bezzine et al (2000) showed a 2.5-fold selectivity of
LY-311727 in vitro in inhibiting human group IIA versus group X,
which is only modest and probably not enough to distinguish
between these two enzymes in cell studies. Therefore, LY-311727
can only be considered as a general inhibitor of sPLA2 activity with
a broad speci®city for the different sPLA2 subtypes. Pyr-1, another
sPLA2 inhibitor that has a 120-fold selectivity for human group IIA
compared with human group X sPLA2 in vitro (Bezzine et al, 2000),
had no inhibitory effect on the sPLA2 activity and fatty acid release
in HaCaT cells (data not shown), strongly suggesting that group IIA
sPLA2 activity does not contribute to these processes. Up to now,
no speci®c inhibitor of the group X sPLA2 is available. It would be
very interesting to study the effects of such a speci®c inhibitor on
epidermis in vivo, as suppression of sPLA2 activity in general has
been shown to disrupt the permeability barrier and to disturb
epidermal homeostasis (Mao-Qiang et al, 1995). According to the
selective expression and the characteristics of enzymatic activity (see
above) group X sPLA2 appears to be the PLA2 subtype involved in
the maintenance of epidermal integrity and function.
We cannot exclude that cytosolic PLA2s also contribute to fatty
acid release from HaCaT cells. Treatment of the cells with methyl
arachidonyl ¯uorophosphonate, a potent inhibitor of this enzyme
and, with a lower potency, of a Ca2+-independent cytosolic PLA2
(group VI PLA2; Balsinde et al, 1999), inhibited the release of linoleic
acid by 20%±30%, but not that of oleic acid, from HaCaT cells.
Selectivity for thehydrolysis of polyunsaturated fatty acids is known to
be a characteristic property of group IV cytosolic PLA2. The fact that
all fatty acids were at least partially reduced by LY-311727, however,
supports the involvement of an sPLA2 in this process.
Figure 6. Effect of TPA treatment on sPLA2 activity and fatty acid
release in HaCaT cells. (a) sPLA2 activity; (b) fatty acid release. Cells
were treated for 8 h with TPA (1 mM). Supernatants were collected and
sPLA2 activity was measured as described in Methods. Each value represents
the mean of three independent experiments 6 SEM (n = 3). *p < 0.05,
Student's t test. Cells were prelabeled with different [1-14C]-labeled fatty
acids (each 0.3 mCi per ml) as indicated. After medium change cells were
further incubated for 8 h in the absence or presence of TPA (1 mM).
Analysis of fatty acids released into the cell culture supernatants was
performed as described in Methods. Each value represents the mean of three
independent experiments 6 SEM (n = 3). #p < 0.05 (oleic acid), +p < 0.05
(linoleic acid), Student's t test.
Figure 7. Time course of the mRNA expression of groups X, IIA,
and V sPLA2 and modulation by phorbol ester TPA. Detection of
mRNA expression of groups X, IIA, and V sPLA2 and the effects of TPA
on their mRNA levels was performed by a semiquantitative RT-PCR as
described in Methods. The data are representative for three separate
experiments with similar results. Abbreviations: C, control; T, TPA.
Figure 8. Northern blot analysis of the effect of TPA on group X
sPLA2 mRNA expression. Northern blot analysis was performed as
described in Methods. The numbers at the top of the northern blot represent
the corrected density expressed as the percentage of group X sPLA2
mRNA found in cells at time point zero.
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A disruption of the epidermal layers occurs during in¯ammatory
processes in the skin. In this respect the phorbol ester TPA, which
is used as a tumor promoter in the mouse multistage skin
carcinogenesis model (for review, see Marks and FuÈrstenberger,
1990), is per se a potent in¯ammatory substance leading to
hyperplasia and hyperkeratosis. Moreover, TPA is a strong activator
of cytosolic PLA2 in mouse keratinocytes resulting in increased
release of arachidonic acid and subsequent eicosanoid formation
(Kast et al, 1993; Lo et al, 1998) through induction of
cyclooxygenase 2 (Scholz et al, 1995; MuÈller-Decker et al, 1998)
and lipoxygenase gene expression (Krieg et al, 1998). Incubation of
HaCaT cells as a human keratinocyte model with TPA reduced
sPLA2 activity by about 50% and fatty acid release by about 40%.
We reported here that all the sPLA2 subtypes IIA, V, and X were
downregulated by TPA at the transcriptional level in HaCaT cells.
A clear decrease of sPLA2 enzyme activity and fatty acid release was
observed in parallel. TPA was also found to inhibit the cytokine-
induced mRNA expression and activity of group IIA sPLA2 in rat
mesangial cells (Scholz et al, 1999). Whether or not TPA elicits
similar effects in skin in vivo remains to be elucidated. A hallmark of
TPA action both in mouse and in human skin is the induction of
in¯ammatory processes (Marks and FuÈrstenberger, 1990). In fact,
certain sPLA2 subtypes, which are expressed at very low levels in
healthy skin, are upregulated under in¯ammatory conditions on
mRNA and protein level and might contribute to proin¯ammatory
eicosanoid formation such as group IIA sPLA2 in activated
keratinocytes (Rys-Sikora et al, 2000) and psoriatic tissue
(Andersen et al, 1994), or group V in mouse macrophages or mast
cells (Balboa et al, 1996; Reddy et al, 1997; Bingham et al, 1999).
A role of group X sPLA2 in the TPA-stimulated early release of
arachidonic acid from HaCaT cells might be hypothesized, as it was
shown that human group X sPLA2 releases arachidonic acid for
cyclooxygenase-2-dependent prostaglandin E2 formation when
added exogenously to adherent mammalian cells (Bezzine et al,
2000). From the time course of downregulation of group X sPLA2
starting between 4 and 8 h, however, and that of phorbol-ester-
induced prostaglandin formation starting after 6±8 h, we suggest
that group X sPLA2-catalyzed arachidonic acid release is not a
prerequisite for the initiation of prostaglandin synthesis induced by
TPA. This was supported by the observation that treatment of the
cells with TPA in the presence of 50 mM of LY-311727, which
signi®cantly reduced fatty acid release, did not result in reduced
prostaglandin E2 formation (unpublished observation).
The mechanism by which TPA downregulates the different
sPLA2 subtypes in HaCaT cells is unknown. TPA was shown to
activate different transcription factors such as AP-1 and ets via
protein kinase C (Dong et al, 1997; Sark et al, 1998), which may
result in inhibition of sPLA2 gene expression. Another possibility is
the modulation of the cytokine-induced signaling pathway up-
stream of the transcription. In this respect we found that TPA-
activated protein kinase C inhibits IL-1b-stimulated activation of a
neutral sphingomyelinase during the ®rst 10 min after treatment of
mesangial cells (Kaszkin et al, 1998), indicating that TPA interferes
with an IL-1-receptor-associated signaling molecule such as the IL-
1-receptor-associated kinase or other IL-1b-activated downstream
kinases (for review, see Auron, 1998).
On the other hand this raised the question: what triggers the
permanent release of group X sPLA2 into the supernatant of
proliferating keratinocytes? These cells are known to spontaneously
release growth factors such as vascular endothelial growth factor
(VEGF) (Weninger et al, 1998; Charvat et al, 1999) and cytokines
such as IL-6 (Aragane et al, 1996). It might be speculated that such
cytokines maintain a constant secretion of group X sPLA2 in an
autocrine manner. In skin repair processes these cytokines have
important functions in stimulating mechanisms crucial for wound
healing such as induction of VEGF expression or formation of
nitric oxide (Frank et al, 1995, 1998). These factors are necessary for
angiogenesis, wound closing, and epidermal reorganization. It
seems reasonable to propose also a physiologic role of group X
sPLA2 in keratinocytes in these processes, which has to be
investigated in future studies. TPA might interfere with group X
sPLA2 secretion by inhibiting the cytokine-mediated signal
transduction. Future studies will further elucidate the mechanisms
of the negative modulation of sPLA2 induced by TPA.
We thank Dr. Wonhwa Cho for the human recombinant group V sPLA2 protein,
and Dr. Heiko MuÈhl for help in performing the semiquantitative PCR. We thank
Dr. Karin MuÈller-Decker from the Cancer Research Center, FSP Tumor Cell
Regulation, for helpful discussion and Silke Spitzer for excellent technical assistance.
The HaCaT cells were kindly provided by Dr. Petra Boukamp from the German
Cancer Research Center, FSP Tumor Cell Regulation. Human primary
keratinocytes were a generous gift from Dr. A. Bernd, Institute of Dermatology
and Venerology, University Hospital Frankfurt, Germany. Human skin biopsies
were a generous gift from Dr. J. Schweizer (German Cancer Research Center,
Heidelberg, Germany). This work was supported by the Deutsche Krebshilfe/Dr.
Mildred Scheel-Stiftung and by the Paul and Cilly Weill-Stiftung.
REFERENCES
Andersen S, Sjursen W, Laegreid A, Volden G, Johansen B: Elevated expression of
human nonpancreatic phospholipase A2 in psoriatic tissue. In¯ammation 18:1±
12, 1994
Aragane Y, Yamada H, Schwarz A, Poppelmann B, Luger TA, Tezuka T, Schwarz
T: Transforming growth factor-alpha induces interleukin-6 in the human
keratinocyte cell line HaCaT mainly by transcriptional activation. J Invest
Dermatol 106:1192±1197, 1996
Auron PE: The interleukin 1 receptor: ligand interactions and signal transduction.
Cytokine Growth Factor Rev 9:221±237, 1998
Balboa MA, Balsinde J, Winstead MV, Tisch®eld JA, Dennis EA: Novel group V
phospholipase A2 involved in arachidonic acid mobilization in murine P388D1
macrophages. J Biol Chem 271:32381±32384, 1996
Balsinde J, Balboa MA, Insel PA, Dennis EA: Regulation and inhibition of
phospholipase A2. Annu Rev Pharmacol Toxicol 39:175±189, 1999
Bezzine S, Koduri RS, Valentin E, et al: Exogenously added human group X secreted
phospholipase A2 but not the group IB, IIA, and V enzymes ef®ciently release
arachidonic acid from adherent mammalian cells. J Biol Chem 275:3179±3191,
2000
Bingham CO, 3rd Fijneman RJ, Friend DS, Goddeau RP, Rogers RA, Austen KF,
Arm JP: Low molecular weight group IIA and group V phospholipase A2
enzymes have different intracellular locations in mouse bone marrow-derived
mast cells. J Biol Chem 274:31476±31484, 1999
Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE:
Normal keratinization in a spontaneously immortalized aneuploid human
keratinocyte cell line. J Cell Biol 106:761±771, 1988
Charvat S, Duchesne M, Parvaz P, Chignol MC, Schmitt D, Serres M: The up-
regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell
lines is reduced by a farnesyl transferase inhibitor. Anticancer Res 19:557±561,
1999
Chen J, Shao C, Lazar V, Srivastava CH, Lee WH, Tisch®eld JA: Localization of
group IIc low molecular weight phospholipase A2 mRNA to meiotic cells in
the mouse. J Cell Biochem 64:369±375, 1997
Chen Y, Dennis EA: Expression and characterization of human group V
phospholipase A2. Biochim Biophys Acta 1394:57±64, 1998
Cupillard L, Koumanov K, Mattei MG, Lazdunski M, Lambeau G: Cloning,
chromosomal mapping, and expression of a novel human secreted
phospholipase A2. J Biol Chem 272:15745±15752, 1997
Dong Z, Crawford HC, Lavrovsky V, Taub D, Watts R, Matrisian LM, Colburn
NH: A dominant negative mutant of jun blocking 12-O-
tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes.
Mol Carcinog 19:204±212, 1997
Frank S, HuÈbner G, Breier G, Longaker MT, Greenhalgh DG, Werner S:
Regulation of vascular endothelial growth factor expression in cultured
keratinocytes. Implications for normal and impaired wound healing. J Biol
Chem 270:12607±12613, 1995
Frank S, Madlener M, Pfeilschifter J, Werner S: Induction of inducible nitric oxide
synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing
enzyme GTP-cyclohydrolase I during cutaneous wound repair. J Invest
Dermatol 111:1058±1064, 1998
Grass DS, Felkner RH, Chiang MY, Wallace RE, Nevalainen TJ, Bennett CF,
Swanson ME: Expression of human group II PLA2 in transgenic mice results in
epidermal hyperplasia in the absence of in¯ammatory in®ltrate. J Clin Invest
97:2233±2241, 1996
Han SK, Kim KP, Koduri R, et al: Roles of Trp31 in high membrane binding and
proin¯ammatory activity of human group V phospholipase A2. J Biol Chem
274:11881±11888, 1999
Hanasaki K, Ono T, Saiga A, et al: Puri®ed group X secretory phospholipase A2
induced prominent release of arachidonic acid from human myeloid leukemia
cells. J Biol Chem 274:34203±34211, 1999
Hurt-Camejo E, Andersen S, Standal R, Rosengren B, Sartipy P, Stadberg E,
Johansen B: Localization of nonpancreatic secreted phospholipase A2 in normal
38 SCHADOW ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
and atherosclerotic arteries. Activity of the isolated enzyme on low-density
lipoproteins. Arterioscler Thromb Vasc Biol 17:300±309, 1997
Ishizaki J, Suzuki N, Higashino K, et al: Cloning and characterization of novel mouse
and human secreted phospholipase A2s. J Biol Chem 274:24973±24979, 1999
Jamal OS, Conaghan PG, Cunningham AM, Brooks PM, Munro VF, Scott KF:
Increased expression of human group IIa secreted phospholipase A2 antigen in
arthritic synovium. Ann Rheum Dis 57:550±558, 1998
Janssen MJ, Vermeulen L, Van der Helm HA, Aarsman AJ, Slotboom AJ, Egmond
MR: Enzymatic properties of rat group IIA and V phospholipases A2
compared. Biochim Biophys Acta 1440:59±72, 1999
Kast R, FuÈrstenberger G, Marks F: Phorbol ester TPA- and bradykinin-induced
arachidonic acid release from keratinocytes is catalyzed by a cytosolic
phospholipase A2 (cPLA2). J Invest Dermatol 101:567±572, 1993
Kaszkin M, Huwiler A, Scholz K, van den Bosch H, Pfeilschifter J: Negative
regulation of interleukin-1b-activated neutral sphingomyelinase by protein
kinase C in rat mesangial cells. FEBS Lett 440:163±166, 1998
Krieg P, Kinzig A, Heidt M, Marks F, Furstenberger G: cDNA cloning of a 8-
lipoxygenase and a novel epidermis-type lipoxygenase from phorbol ester-
treated mouse skin. Biochim Biophys Acta 1391:7±12, 1998
Laemmli UK: Cleavage of structural proteins during assembly of the head of
bacteriophage T4. Nature 227:680±685, 1970
Lampe MA, Burlingame AL, Whitney J, Williams ML, Brown BE, Roitman E, Elias
PM: Human stratum corneum lipids: characterization and regional variations. J
Lipid Res 24:120±130, 1983
Lo HH, Teichmann P, Furstenberger G, Gimenez-Conti I, Fischer SM: Suppression
or elevation of cytosolic phospholipase A2 alters keratinocyte prostaglandin
synthesis, growth, and apoptosis. Cancer Res 58:4624±4631, 1998
Mao-Qiang M, Feingold KR, Jain M, Elias PM: Extracellular processing of
phospholipids is required for permeability barrier homeostasis. J Lipid Res
36:1925±1935, 1995
Mao-Qiang M, Jain M, Feingold KR, Elias PM: Secreted phospholipase A2 activity is
required for permeability barrier homeostasis. J Invest Dermatol 106:57±63, 1996
Marks F, FuÈrstenberger G: The conversion stage of skin carcinogenesis. Carcinogenesis
11:2085±2092, 1990
Matsuda Y, Ogawa M, Shibata T, Nakaguchi K, Nishijima J, Wakasugi C, Mori T:
Distribution of immunoreactive pancreatic phospholipase A2 (IPPL-2) in
various human tissues. Res Commun Chem Pathol Pharmacol 58:281±284, 1987
Maury E, Prevost MC, Simon MF, et al: Identi®cation of two secreted phospholipases
A2 in human epidermis. J Invest Dermatol 114:960±966, 2000
Mazereeuw-Hautier J, Redoules D, Tarroux R, et al: Identi®cation of pancreatic
type I secreted phospholipase A2 in human epidermis and its determination by
tape stripping. Br J Dermatol 142:424±431, 2000
MuÈller-Decker K, Scholz K, Neufang G, Marks F, FuÈrstenberger G: Localization of
prostaglandin-H synthase-1 and ±2 in mouse skin: implications for cutaneous
function. Exp Cell Res 242:84±91, 1998
Murakami M, Shimbara S, Kambe T, Kuwata H, Winstead MV, Tisch®eld JA, Kudo
I: The functions of ®ve distinct mammalian phospholipase A2s in regulating
arachidonic acid release. Type IIa and type V secreted phospholipase A2s are
functionally redundant and act in concert with cytosolic phospholipase A2. J
Biol Chem 273:14411±14423, 1998
Murakami M, Kambe T, Shimbara S, et al: Different functional aspects of the group II
subfamily (types IIA and V) and type X secretory phospholipase A2s in
regulating arachidonic acid release and prostaglandin generation. Implications
of cyclooxygenase-2 induction and phospholipid scramblase-mediated cellular
membrane perturbation. J Biol Chem 274:31435±31444, 1999
Nair X, Nettleton D, Clever D, Tramposch KM, Ghosh S, Franson RC: Swine as a
model of skin in¯ammation. Phospholipase A2-induced in¯ammation.
In¯ammation 17:205±215, 1993
Pfeilschifter J: Mesangial cells orchestrate in¯ammation in the renal glomerulus. News
Physiol Sci 9:271±276, 1994
Pfeilschifter J. Control of phospholipase A2 gene expression. In: Glaser KB, Vadas P,
eds. Molecular Approaches to Pathophysiology, New York: CRC Press, 1995: pp
25±51
Pfeilschifter J, Schalkwijk C, Briner VA, van den Bosch H: Cytokine-stimulated
secretion of group II phospholipase A2 by rat mesangial cells. Its contribution to
arachidonic acid release and prostaglandin synthesis by cultured rat glomerular
cells. J Clin Invest 92:2516±2523, 1993
Pfeilschifter J, Walker G, Kunz D, Pignat W, Van den Bosch H: Phospholipase A2.
Basic and clinical aspects in in¯ammatory diseases. In: Uhl W, Nevalainen TJ,
BuÈchler MW, eds. Progress in Surgery, Vol 24, Basel: Karger, 1997: pp 31±37
Pruzanski W, Vadas P, Fornasier V: In¯ammatory effect of intradermal administration
of soluble phospholipase A2 in rabbits. J Invest Dermatol 86:380±383, 1986
Pruzanski W, Stefanski E, Vadas P, Kennedy BP, van den Bosch H: Regulation of
the cellular expression of secretory and cytosolic phospholipases A2, and
cyclooxygenase-2 by peptide growth factors. Biochim Biophys Acta 1403:47±56,
1998
Reddy ST, Winstead MV, Tisch®eld JA, Herschman HR: Analysis of the secretory
phospholipase A2 that mediates prostaglandin production in mast cells. J Biol
Chem 272:13591±13596, 1997
Redoules D, Tarroux R, Perie J: Epidermal enzymes: their role in homeostasis and
their relationships with dermatoses. Skin Pharmacol Appl Skin Physiol 11:183±
192, 1998
Rys-Sikora KE, Konger RL, Schoggins JW, Malaviya R, Pentland AP: Coordinate
expression of secretory phospholipase A2 and cyclooxygenase-2 in activated
human keratincytes. Am J Physiol Cell Physiol 278:C822±C833, 2000
Sambrook J, Frotscj J, Maniatis T: Molecular Cloning: a Laboratory Manual. New York:
Cold Spring Harbor Laboratory Press, 1989
Sark MW, Fischer DF, de Meijer E, van de Putte P, Backendorf C: AP-1 and ets
transcription factors regulate the expression of the human SPRR1A
keratinocyte terminal differentiation marker. J Biol Chem 273:24683±24692,
1998
Sawada H, Murakami M, Enomoto A, Shimbara S, Kudo I: Regulation of type V
phospholipase A2 expression and function by proin¯ammatory stimuli. Eur J
Biochem 263:826±835, 1999
Schevitz RW, Bach NJ, Carlson DG, et al: Structure-based design of the ®rst potent
and selective inhibitor of human non-pancreatic secreted phospholipase A2.
Nat Struct Biol 2:458±465, 1995
Schiering A, Menschikowski M, Mueller E, Jaross W: Analysis of secreted group II
phospholipase A2 expression in human aortic tissue in dependence on the
degree of atherosclerosis. Atherosclerosis 144:73±78, 1999
Scholz K, FuÈrstenberger G, MuÈller-Decker K, Marks F: Differential expression of
prostaglandin-H synthase isoenzymes in normal and activated keratinocytes in
vivo and in vitro. Biochem J 309:263±269, 1995
Scholz K, Vlachojannis GJ, Spitzer S, Schini-Kerth V, Van Den Bosch H, Kaszkin M,
Pfeilschifter J: Modulation of cytokine-induced expression of secretory
phospholipase A2-type IIA by protein kinase C in rat renal mesangial cells.
Biochem Pharmacol 58:1751±1758, 1999
Shinohara H, Balboa MA, Johnson CA, Balsinde J, Dennis EA: Regulation of
delayed prostaglandin production in activated P388D1 macrophages by group
IV cytosolic and group V secreted phospholipase A2s. J Biol Chem 274:12263±
12268, 1999
Shoda J, Kano M, Asano T, et al: Secreted low-molecular-weight phospholipases A2
and their speci®c receptor in bile ducts of patients with intrahepatic calculi:
factors of chronic proliferative cholangitis. Hepatology 29:1026±1036, 1999
Stein M, Bernd A, Ramirez-Bosca A, Kippenberger S, Holzmann H: Measurement
of anti-in¯ammatory effects of glucocorticoids on human keratinocytes in vitro.
Comparison of normal human keratinocytes with the keratinocyte cell line
HaCaT. Arzneimittelforschung/Drug Res 47:1266±1270, 1997
Suzuki N, Ishizaki J, Yokota Y, et al: Structures, enzymatic properties, and expression
of novel human and mouse secretory phospholipase A2s. J Biol Chem 275:5785±
5793, 2000
Thommesen L, Sjursen W, Gasvik K, et al: Selective inhibitors of cytosolic or
secretory phospholipase A2 block TNF-induced activation of transcription
factor nuclear factor-kappa B and expression of ICAM-1. J Immunol 161:3421±
3430, 1998
Tinois E, Kanitakis J, Faure M: Lamellar bodies in cultured human keratinocytes. J
Invest Dermatol 92:132, 1989
Tisch®eld JA: A reassessment of the low molecular weight phospholipase A2 gene
family in mammals. J Biol Chem 272:17247±17250, 1997
Valentin E, Koduri RS, Scimeca JC, Carle G, Gelb MH, Lazdunski M, Lambeau G:
Cloning and recombinant expression of a novel mouse-secreted phospholipase
A2. J Biol Chem 274:19152±19160, 1999
Vervoordeldonk MJ, Schalkwijk CG, Vishwanath BS, Aarsman AJ, van den Bosch
H: Levels and localization of group II phospholipase A2 and annexin I in
interleukin- and dexamethasone-treated rat mesangial cells: evidence against
annexin mediation of the dexamethasone-induced inhibition of group II
phospholipases A2. Biochim Biophys Acta 1224:541±550, 1994
Weninger W, Rendl M, Mildner M, Tschachler E: Retinoids downregulate vascular
endothelial growth factor/vascular permeability factor production by normal
human keratinocytes. J Invest Dermatol 111:907±911, 1998
Ziboh VA, Miller CC, Cho Y: Metabolism of polyunsaturated fatty acids by skin
epidermal enzymes: generation of antiin¯ammatory and antiproliferative
metabolites. Am J Clin Nutr 71:361S±366S, 2000
VOL. 116, NO. 1 JANUARY 2001 SECRETED PHOSPHOLIPASES A2 IN HUMAN KERATINOCYTES 39
